Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus+Ruxolitinib+MMF for aGvHD Prophylaxis in Haplo-HSCT Patients Intolerant to CNI
NCT07796620Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2026
- Primary completion
- Sep 2027
01
Overview
A Phase 2 trial of sirolimus in graft-versus-host disease (GVHD), sponsored by Peking University People's Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07796620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07796620.